Search / Trial NCT06233994

A Study Evaluating the Efficacy and Safety of ZG005 in Combination With Donafenib or Bevacizumab in Patients With Advanced Hepatocellular Carcinoma

Launched by CHANGSHA TAIHE HOSPITAL · Jan 23, 2024

Trial Information

Current as of October 09, 2024

Not yet recruiting

Keywords

Description

No description provided

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • * Male or female ≥18 years of age.
  • * Fully understand the study and voluntarily sign the informed consent form.
  • * Histologically or cytologically confirmed diagnosis of metastatic or unresectable hepatocellular carcinoma (HCC).
  • * Life expectancy \>= 3 months.
  • * Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.
  • Exclusion Criteria:
  • * Fibrolamellar or sarcomatoid HCC, or mixed cholangiocarcinoma and HCC.
  • * Patients were deemed unsuitable for participating in the studyl by the investigator for any reasons.

About Changsha Taihe Hospital

Changsha Taihe Hospital is a leading medical institution located in Changsha, China, dedicated to advancing healthcare through innovative research and clinical trials. With a commitment to improving patient outcomes and contributing to the global medical community, the hospital specializes in a range of medical disciplines, leveraging state-of-the-art technology and a team of experienced healthcare professionals. By conducting rigorous clinical trials, Changsha Taihe Hospital aims to evaluate new therapies and interventions, ensuring the highest standards of safety and efficacy while fostering collaboration with academic institutions and industry partners.

Locations

Changsha, Hunan, China

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0